#1 Clinical Trials Search in Europe

Drexlerviridae Bacteriophage Against Klebesiella Pneumoniae (45.423 Bp)

A new clinical trial is underway to evaluate the safety and effectiveness of a novel bacteriophage cocktail called TP-122 for treating ventilator-associated pneumonia (VAP). This Phase 1/2a study aims to assess the safety and tolerability of multiple doses of TP-122, specifically focusing on one of its components, TP-122A. The trial will compare the outcomes of patients receiving TP-122A in addition to standard of care (SoC) treatment versus those receiving SoC alone.

Table of Contents

What is DREXLERVIRIDAE BACTERIOPHAGE?

DREXLERVIRIDAE BACTERIOPHAGE AGAINST KLEBESIELLA PNEUMONIAE (45.423 BP) is a type of virus that specifically targets and kills the bacteria Klebsiella pneumoniae. It is part of a larger treatment called TP-122, which is a bacteriophage cocktail. This means it’s a mixture of different types of bacteriophages designed to fight specific bacteria.[1]

The term “45.423 BP” refers to the size of the bacteriophage’s genetic material, measured in base pairs. This specific information helps scientists identify and characterize the bacteriophage.

Target Condition: Ventilator-Associated Pneumonia

TP-122, which includes the DREXLERVIRIDAE BACTERIOPHAGE, is being studied as a potential treatment for Ventilator-Associated Pneumonia (VAP). VAP is a serious lung infection that can occur in patients who are on mechanical ventilation in hospitals.[1]

Ventilator-Associated Pneumonia typically occurs when harmful bacteria, such as Klebsiella pneumoniae, enter the lungs of a patient on a ventilator. This can lead to severe complications and longer hospital stays.

How It Works

Bacteriophages, like DREXLERVIRIDAE BACTERIOPHAGE, work by specifically targeting and destroying bacteria. They do this without harming human cells, which is different from how many antibiotics work. In the case of this treatment:

  1. The bacteriophage recognizes and attaches to Klebsiella pneumoniae bacteria.
  2. It injects its genetic material into the bacteria.
  3. The bacteriophage uses the bacteria’s own machinery to replicate itself.
  4. Eventually, the bacteria burst, releasing more bacteriophages to target other Klebsiella pneumoniae bacteria.

Clinical Trial Information

A clinical trial is currently underway to study the safety and effectiveness of TP-122, which includes DREXLERVIRIDAE BACTERIOPHAGE. This trial is in Phase 1/2a, which means it’s one of the earliest stages of testing in humans.[1]

Key points about the trial:

  • It’s a randomized, open-label study, meaning participants are randomly assigned to either receive TP-122 or standard care, and both the doctors and patients know which treatment is being given.
  • The treatment is given through nebulization, which means it’s inhaled as a mist, every 8 hours for 7 days.
  • Participants must be adults (18 years or older) with confirmed Ventilator-Associated Pneumonia.
  • The main goal is to assess the safety and how well patients tolerate the treatment.

Potential Benefits

While the effectiveness of this treatment is still being studied, potential benefits may include:

  • Targeted treatment of Klebsiella pneumoniae infections without harming beneficial bacteria
  • Potentially faster recovery from Ventilator-Associated Pneumonia
  • Possible reduction in the length of time patients need mechanical ventilation
  • Potential decrease in the duration of ICU stays

Safety Considerations

As this is an early-stage clinical trial, the safety profile of TP-122 is still being established. The trial is closely monitoring for any side effects or adverse events. Patients with certain conditions, such as severe asthma, active tuberculosis, or those who are immunocompromised, are not eligible for the trial due to potential risks.[1]

Administration

In the clinical trial, TP-122 (which includes DREXLERVIRIDAE BACTERIOPHAGE) is administered through nebulization. This means the medication is turned into a fine mist that can be inhaled directly into the lungs. For patients on ventilators, this can be done through the breathing tube.[1]

Conclusion

DREXLERVIRIDAE BACTERIOPHAGE AGAINST KLEBESIELLA PNEUMONIAE (45.423 BP), as part of the TP-122 treatment, represents a potentially innovative approach to treating Ventilator-Associated Pneumonia. While still in early stages of research, it offers hope for a more targeted treatment option for this serious condition. As with any experimental treatment, it’s important to remember that more research is needed to fully understand its effectiveness and safety profile.

Aspect Details
Study Type Randomized, Parallel, Open-Label, Phase 1/2a
Intervention TP-122A (bacteriophage cocktail) + Standard of Care
Control Standard of Care alone
Primary Objective Safety and tolerability of TP-122A
Secondary Objectives Clinical cure rate, microbiological response, mechanical ventilation duration, ICU stay length, survival rate
Key Inclusion Criteria Adults with VAP, stable ventilatory requirements, P. aeruginosa infection
Key Exclusion Criteria Recent cancer treatment, severe asthma, immunocompromised status, pregnancy
Treatment Duration 7 days
Follow-up Two follow-up periods (FUp1 and FUp2)

FAQ

  • What is TP-122 and how does it work? TP-122 is a bacteriophage cocktail designed to treat ventilator-associated pneumonia. It contains multiple types of bacteriophages, which are viruses that specifically target and kill bacteria. In this case, TP-122 targets bacteria like Klebsiella pneumoniae and Pseudomonas aeruginosa, which are common causes of VAP.
  • Who is eligible to participate in this clinical trial? Eligible participants are adults (18 years or older) with ventilator-associated pneumonia who meet specific criteria, including stable ventilatory requirements and a microbiological diagnosis of P. aeruginosa infection in the lower respiratory tract. Certain medical conditions and treatments may exclude individuals from participating.
  • How is TP-122A administered in the trial? TP-122A is administered through nebulization, which means it is inhaled as a mist. Participants receive multiple doses every 8 hours for 7 days, in addition to standard of care treatment for VAP.
  • What are the main objectives of this clinical trial? The primary objective is to evaluate the safety and tolerability of TP-122A when given in addition to standard care. Secondary objectives include assessing clinical cure rates, time to achieve clinical cure, microbiological response, duration of mechanical ventilation, length of ICU stay, and survival rates.
  • How long does the trial last for each participant? The trial includes a 7-day treatment period followed by two follow-up periods. The exact duration is not specified in the provided information, but it likely extends several weeks beyond the initial treatment phase to assess longer-term outcomes and safety.

Ongoing Clinical Trials on Drexlerviridae Bacteriophage Against Klebesiella Pneumoniae (45.423 Bp)

  • Safety and tolerability study of bacteriophage cocktail TP-122A given by inhalation in adults with ventilator-associated pneumonia

    Not yet recruiting

    2 1 1
    Investigated drugs:
    The Netherlands Portugal

  • Study on the Safety and Tolerability of TP-122 for Treating Ventilator-Associated Pneumonia in Adults

    Not yet recruiting

    2 1 1
    Investigated drugs:
    France

Glossary

  • Ventilator-Associated Pneumonia (VAP): A type of lung infection that occurs in people who are on mechanical ventilation breathing machines in hospitals.
  • Bacteriophage: A virus that infects and replicates within bacteria. In this context, bacteriophages are being used as a potential treatment for bacterial infections.
  • Standard of Care (SoC): The currently accepted method of treating a disease or condition, typically used as a comparison for new treatments in clinical trials.
  • Nebulization: The process of converting a liquid into a fine spray or mist, often used to administer medications directly to the lungs.
  • Clinical Cure: The resolution or significant improvement of signs and symptoms related to the infection, indicating successful treatment.
  • Microbiological Response: The effect of treatment on the bacteria causing the infection, such as eradication or reduction in bacterial numbers.
  • Adverse Events (AEs): Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • Serious Adverse Events (SAEs): Adverse events that result in death, are life-threatening, require hospitalization, or cause significant disability.
  • Mechanical Ventilation: The use of a machine to help a patient breathe by moving breathable air into and out of the lungs.
  • Intensive Care Unit (ICU): A specialized hospital department that provides intensive care medicine to critically ill patients.

References

  1. http://clinicaltrials.eu/trial/study-on-the-safety-and-tolerability-of-tp-122-for-treating-ventilator-associated-pneumonia-in-adults/